Vivos (VVOS) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Full-year revenue increased by 16% to $17 million, driven by a $4.8 million rise in sleep testing services and $2.2 million from treatment at the Sleep Center of Nevada (SCN). However, this was partially offset by a $1.4 million decline in product revenue from legacy VIP dentists and a $2 million drop in VIP enrollment revenue.

Gross Profit: Increased to $10.5 million (60% gross margin), up from $9 million in 2024.

Operating Expenses: Rose significantly to $30.4 million from $20.2 million, primarily due to increased general and administrative costs associated with the SCN acquisition.

Net Loss: Increased to $21.2 million, reflecting higher costs from the strategic transition.

Cash Position: As of December 31, 2025, Vivos had $2 million in cash and total liabilities of $26.7 million, up from $7.3 million in 2024.

2Strategic Updates and Business Highlights

Vivos completed the acquisition of SCN in June 2025, marking a pivotal shift towards a medical provider-focused business model.

The company has received in-network status with several commercial health insurance payers, enhancing patient access to treatments.

The introduction of Sleep Optimization (SO) teams aims to improve patient education and treatment uptake.

Vivos plans to expand its diagnostic and treatment services, including a pediatric OSA program and collaborations with specialty medical groups.

3Forward Guidance and Outlook

Vivos anticipates stronger revenue growth in 2026, driven by increased patient demand and the successful integration of SCN.

The company aims to achieve cash flow positive operations by the end of 2026, requiring a revenue run rate close to double that of 2025.

Continued expansion of the SO teams and further insurance participation are expected to bolster revenue.

4Bad News, Challenges, or Points of Concern

Q4 Revenue Decline: Revenue dropped to $3.8 million in Q4 from $6.8 million in Q3, attributed to provider absences and challenges in maintaining sufficient staffing levels.

Increased Costs: Significant one-time expenses related to the SCN acquisition and integration have contributed to the net loss.

Provider Recruitment Issues: The company faced unexpected provider attrition in Q4, impacting service delivery and revenue generation. Although recruitment efforts are underway, this remains a concern for operational stability.

5Notable Q&A Insights

Q4 Performance Explanation: CEO Kirk Huntsman explained that the decline in Q4 revenue was due to unforeseen provider absences, which have since been addressed with additional recruitment.

Future Revenue Expectations: Huntsman indicated that Q1 2026 is expected to show improvement, with more significant gains anticipated in Q2 as new providers become fully operational and in-network insurance coverage begins to impact revenue.

Long-Term Growth Strategy: The company is optimistic about its new affiliation model, which is more capital-efficient than acquisitions, allowing for rapid expansion across various markets.

Patient Demand: There is strong interest from specialty medical groups in Vivos' treatments, indicating a growing market for their services. Overall, while Vivos is navigating challenges related to staffing and integration, the strategic pivot towards a medical provider-focused model and the acquisition of SCN are seen as significant steps towards future growth and profitability.